Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

LONDON , Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which terminates December 31, 2024, under which the Company repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024.

Clarivate Announces New $500 Million Share Repurchase Authorization

Faster and more relevant results to empower critical IP decision-making LONDON , Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in less time.

Clarivate Launches AI-Powered Patent Search Solution in Derwent

Nine Energy Service

Prospect Capital

It's widely believed that insiders know how well a company is operating. Therefore, when insiders are actively buying their stock, it is assumed they must know something that's motivating them to buy shares.

Bargains Galore? 3 Stocks With Insider Buying in the Millions

Revealing highly active specialties in sciences and social sciences LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.

Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts

Enhancing operational efficiency for leading air conditioner manufacturer LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Daikin Industries, Ltd. (Daikin) has selected IPfolio™ from Clarivate.

Daikin Selects IPfolio from Clarivate

New seven-part series explores disparities in care, funding and innovation impacting half the world's population LONDON , Nov. 21, 2024 /PRNewswire/ --  BioWorld ™ published by  Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide. ' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment.

BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series

Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON , Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,636 Highly Cited Researchers in 2024 from more than 1,200 institutions in 59 nations and regions.

Clarivate Reveals Highly Cited Researchers 2024 List

New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON , Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come . Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches.

New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence

Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital Groups LONDON , Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners of the Clarivate Healthcare Business Insights™ annual Revenue Cycle Awards. Now in its 12th year, the Revenue Cycle Awards recognize U.S.-based healthcare organizations for exceptional performance on revenue cycle KPIs, based on data from their most recent and preceding full fiscal years.

Clarivate Healthcare Business Insights Unveils 2023 Revenue Cycle Award Winners

LONDON , Nov. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has today published its fourth annual sustainability report, showcasing its commitment to sustainability and the United Nations Sustainable Development Goals (SDGs). In 2023, Clarivate was shortlisted for the SDG Pioneer Award at the Thomson Reuters Responsible Business Awards.

Clarivate Publishes 2023 Sustainability Report

I downgrade Clarivate PLC from buy to hold due to lack of confidence in near-term organic growth recovery and potential further stock price decline. CLVT's 3Q24 earnings report showed a 3.9% revenue decline and worsening organic growth, marking the worst performance in its history. The new CEO's Value Creation Plan is promising but will take a long time to show results, adding to the uncertainty.

Clarivate: Downgrade To Hold As Growth May Take A Long Time To Recover

ProQuest One Sustainability offers a transdisciplinary research experience and features AI-powered ProQuest Research Assistant LONDON , Nov. 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of ProQuestTM One Sustainability. The new solution is an expansive, curated, multi-format content collection designed to meet the growing demand for sustainability curricula across research, teaching and learning.

Clarivate Launches New Sustainability Research Solution

Clarivate Plc (NYSE:CLVT ) Q3 2024 Earnings Conference Call November 6, 2024 9:00 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Matti Shem Tov - Chief Executive Officer Jonathan Collins - Chief Financial Officer Conference Call Participants Owen Lau - Oppenheimer David Paige - RBC Toni Kaplan - Morgan Stanley Andrew Nicholas - William Blair Manav Patnaik - Barclays Shlomo Rosenbaum - Stifel Peter Christiansen - Citi George Tong - Goldman Sachs Colton Feldmann - Jefferies Operator Hello, and thank you for standing by. My name is Regina and I will be your conference operator today.

Clarivate Plc (CLVT) Q3 2024 Earnings Call Transcript

The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Clarivate (CLVT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Clarivate PLC (CLVT) came out with quarterly earnings of $0.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.21 per share a year ago.

Clarivate PLC (CLVT) Matches Q3 Earnings Estimates

LONDON , Nov. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2024. Third  Quarter 2024 Financial Highlights Revenues of $622.2 million decreased 3.9% Organic revenues decreased 2.6%, as an increase in subscription revenues of 0.6% was offset by a decrease in re-occurring revenues of 1.1% and transactional and other revenues of 13.6% Net loss of $65.6 million; Net loss per diluted share of $0.09 Adjusted net income(1) of $134.1 million decreased 12.1%; Adjusted diluted EPS(1) of $0.19 decreased 9.5% or $0.02 Adjusted EBITDA(1) of $264.4 million decreased 6.0%; Adjusted EBITDA margin(1) of 42.5% decreased 100 basis points primarily due to lower revenues Net cash provided by operating activities of $202.9 million increased $39.5 million; Free cash flow(1) of $126.3 million increased $24.6 million primarily due to the timing of working capital Nine Months Ended September 30, 2024 Financial Highlights Revenues of $1,893.7 million decreased 2.6% Organic revenues decreased 1.5% as an increase in subscription revenues of 1.2% was offset by a decline in re-occurring revenues of 2.3% and transactional and other revenues of 9.3% Net loss of $444.9 million; Net loss per diluted share of $0.69 Adjusted net income(1) of $379.8 million decreased 12.8%; Adjusted diluted EPS(1) of $0.52 decreased 11.9% or $0.07 Adjusted EBITDA(1) of $775.1 million decreased 5.4%; Adjusted EBITDA margin(1) of 40.9% decreased 120 basis points primarily due to lower revenues Net cash provided by operating activities decreased $48.0 million to $505.3 million; Free cash flow(1) decreased $76.3 million to $298.4 million primarily due to lower operating income and increased capital expenditures "Clarivate's third quarter results are unsatisfactory and reflect an overdependency on fluctuating transactional revenue and areas of the business with low margin characteristics," said Matti Shem Tov, Chief Executive Officer.

Clarivate Reports Third Quarter 2024 Results

Get a deeper insight into the potential performance of Clarivate (CLVT) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

What Analyst Projections for Key Metrics Reveal About Clarivate (CLVT) Q3 Earnings

Clarivate (CLVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

ST. LOUIS--(BUSINESS WIRE)--Silverchair, a portfolio company of Thompson Street Capital Partners (TSCP), announced today that is has entered into a definitive agreement with Clarivate Plc (NYSE:CLVT) to acquire ScholarOne, a leading provider of software and services to scholarly publishers and societies. Terms of the transaction were not disclosed. Founded in 1993 and based in Charlottesville, VA, Silverchair provides a suite of software and services to leading global publishers of scientific,.

Thompson Street Portfolio Company Silverchair Announces Agreement to Acquire Scholarone

LONDON , Oct. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the third quarter 2024 before the market opens on Wednesday, November 6, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report Third Quarter 2024 Results on November 6, 2024

83 Citation Laureates named by the Institute for Scientific Information have received a Nobel Prize since 2002 LONDON , Oct. 15, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the success of its annual Citation Laureates™ program, following the accurate forecast of eight Nobel Prize 2024 recipients. Powered by trusted, high-quality data from the Web of Science Core Collection™ citation index, the Citation Laureates program combines rigorous citation analysis with expert qualitative insights to pinpoint researchers with exceptional citation records who have the potential to receive Nobel honors.

Clarivate Repeats Success in Nobel Prize Predictions with Eight New Winners Identified by Citation Laureates Program

Top industry leaders to explore AI, data, strategic partnerships, and innovation opportunities in Latin America at premier Life Sciences event LONDON , Oct. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 2nd annual Summit LATAM, which will be held in Milan on October 7, 2024, ahead of the CPHI Milan conference. In partnership with the Brazilian Association of the Pharmaceutical Ingredients Industry (Abiquifi), this year's event reinforces the industry's commitment to patient welfare by showcasing how collective efforts and innovative strategies are reshaping the pharmaceutical ecosystem, with a focus on navigating market challenges and uncovering innovation opportunities.

Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda

LONDON , Sept. 25, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the development of a comprehensive framework for evaluating the societal impact of research.

Clarivate Unveils Comprehensive Framework to Evaluate the Societal Impact of Research

Sharing benchmarks and strategies to elevate IP practices LONDON , Sept. 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released a new survey-based report that reveals insights and best practices for optimizing intellectual property (IP) operations.

New Clarivate Report Reveals Challenges and Trends Shaping IP Operations

Clarivate Medtech Intelligence and Relatable software enhance product data management and competitive conversion efficiency for medtech sales, contracting and pricing teams LONDON , Sept. 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with Relatable Healthcare, a technology company delivering Product Relationship Management (PRM) software to leading medtech companies to drive revenue and workflow efficiency.

News for Clarivate Plc Stock (CLVT)